Supreme Court Rules Companies Cannot Patent Human Genes

The decision may allow others to offer BRCA testing at lower cost. Jean A. Sachs, MSS, MLSP, Living Beyond Breast Cancer’s chief executive officer, and the LBBC staff want to know what you think about this ruling.

2012JeanSachsHeadshotVer2Web

June 14, 2013 – PHILADELPHIA – The nine justices of the U.S. Supreme Court ruled unanimously yesterday in Association for Molecular Pathology v. Myriad Genetics that corporations may not patent human genes because they are products of nature.

“This decision has important implications for all women and families affected by hereditary breast cancer, potentially lowering the costs of genetic tests, increasing access to second opinions, and encouraging unfettered communication among researchers into the causes of disease,” said Jean A. Sachs, MSS, MLSP, CEO of Living Beyond Breast Cancer.

The case focused on Myriad Genetics’ patent claim over BRCA1 and BRCA2, genes that repair damage to cells in all humans. When mutated (damaged) and passed onto a child at birth from the father or mother, BRCA genes dramatically increase a person’s chance of developing breast and ovarian cancer.

“The ruling touches all people concerned about cancer, but we are particularly pleased that it may benefit a number of underserved groups for which we have targeted programs,” Ms. Sachs said. “Premenopausal women, women with triple-negative breast cancer, and African-American women are all known to have a higher incidence of BRCA mutations.”

Until now, only Myriad Genetics could legally offer the test that analyzes the full BRCA1 and BRCA2 genes. Over the next several months, Living Beyond Breast Cancer anticipates:

  • Companies, academic institutions, laboratories and medical facilities with multi-gene assays will begin to offer BRCA testing
  • The cost of genetic testing will drop significantly from its current price of nearly $4,000 to $1,000 or less
  • Individuals who undergo genetic testing will gain the ability to obtain second opinions for positive, negative and uncertain results
  • Increased market competition will allow individuals, facilities and payors to select among a variety of BRCA tests, and each test will have its own strengths and weaknesses
  • More transparency about the BRCA genes will spur research into their role in the development of both hereditary and non-hereditary breast cancers
The case focused on Myriad Genetics' patent clean over BRCA1 and BRCA2, genes that, if mutated (damaged), dramatically increase a person's risk of developing breast and ovaran cancer.

The case focused on Myriad Genetics’ patent claim over BRCA1 and BRCA2, genes that, if mutated, increase a person’s risk of developing breast and ovaran cancer. (image courtesy of Brigham and Women’s Hospital)

The court also ruled that corporations may patent complementary DNA (cDNA), a product created by manipulating human DNA to eliminate parts of the gene. As experts continue to interpret the Supreme Court ruling, the role of cDNA in BRCA and other genetic testing may become clearer.

“This ruling will offer the people we serve more choices—and more information to absorb during treatment decision-making,” Ms. Sachs said. “As a national education organization, Living Beyond Breast Cancer will provide education, tools and support, and help connect women with LBBC volunteers and our colleagues at other organizations to help them get the information they need.”

Living Beyond Breast Cancer offers information about hereditary breast cancers on its website and, working with several collaborating organizations, will release a new brochure in October, the Guide to Understanding Genetics and Family Risk Assessment. For more information about LBBC’s programs and services, visit lbbc.org, and for peer emotional support, call LBBC’s Helpline at (888) 753-LBBC (5222).

We want to know your thoughts on this case. What do you think of the Supreme Court’s decision? What questions or concerns does this case prompt for you? Please share your perspectives in the comment section below or on our Facebook page

Tags: , , , ,

8 Responses to “Supreme Court Rules Companies Cannot Patent Human Genes”

  1. berealblack Says:

    Reblogged this on berealblack.

  2. Ronda Walker Weaver Says:

    Fantastic news. I just paid $6000 for piece of mind. I’d do it again, however, this makes genetic testing available for so many men and women. Thank you for this report.

  3. snrjcernzf@live.com Says:

    Hey there are using WordPress for your blog platform? I’m new to the blog world but I’m trying to get started and set up my own. Do you need any coding knowledge to make your own blog? Any help would be really appreciated!

  4. myroofingcontractor.blogspot.com Says:

    If some one wants to be updated with most up-to-date technologies then he must be go to see this site
    and be up to date every day.

  5. Nelson Says:

    Very good website you have here but I was curious about if you knew
    of any community forums that cover the same topics discussed
    in this article? I’d really like to be a part of
    online community where I can get responses from other knowledgeable individuals that share the same interest.
    If you have any recommendations, please let me know. Kudos!

  6. Layla Says:

    If some one wishes expert view regarding blogging
    and site-building after that i suggest him/her to
    go to see this website, Keep up the nice job.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s


Follow

Get every new post delivered to your Inbox.

Join 196 other followers

%d bloggers like this: